ECSP17054980A - Inhibidores selectivos de bace1 - Google Patents

Inhibidores selectivos de bace1

Info

Publication number
ECSP17054980A
ECSP17054980A ECIEPI201754980A ECPI201754980A ECSP17054980A EC SP17054980 A ECSP17054980 A EC SP17054980A EC IEPI201754980 A ECIEPI201754980 A EC IEPI201754980A EC PI201754980 A ECPI201754980 A EC PI201754980A EC SP17054980 A ECSP17054980 A EC SP17054980A
Authority
EC
Ecuador
Prior art keywords
bace1 inhibitors
selective bace1
selective
inhibitors
compound
Prior art date
Application number
ECIEPI201754980A
Other languages
English (en)
Inventor
Simon James Richards
Timothy Andrew Woods
Leonard Larry Winneroski
Jennifer Anne McMahon
Erik James Hembre
Jose Eduardo Lopez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP17054980A publication Critical patent/ECSP17054980A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/08Malonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto de Fórmula II: o una sal aceptable para uso farmacéutico.
ECIEPI201754980A 2015-02-23 2017-08-22 Inhibidores selectivos de bace1 ECSP17054980A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562119391P 2015-02-23 2015-02-23

Publications (1)

Publication Number Publication Date
ECSP17054980A true ECSP17054980A (es) 2017-11-30

Family

ID=55442893

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201754980A ECSP17054980A (es) 2015-02-23 2017-08-22 Inhibidores selectivos de bace1

Country Status (27)

Country Link
US (1) US9522923B2 (es)
EP (1) EP3262051B1 (es)
JP (1) JP6111001B1 (es)
KR (1) KR101945139B1 (es)
CN (1) CN107257801B (es)
AR (1) AR103680A1 (es)
AU (1) AU2016223072B2 (es)
BR (1) BR112017013936A2 (es)
CA (1) CA2972098A1 (es)
CL (1) CL2017002090A1 (es)
CO (1) CO2017008382A2 (es)
CR (1) CR20170315A (es)
DO (1) DOP2017000178A (es)
EA (1) EA031546B1 (es)
EC (1) ECSP17054980A (es)
GT (1) GT201700185A (es)
IL (1) IL252969A0 (es)
MX (1) MX367940B (es)
NZ (1) NZ732940A (es)
PE (1) PE20171337A1 (es)
PH (1) PH12017501523A1 (es)
SG (1) SG11201705764SA (es)
SI (1) SI3262051T1 (es)
TN (1) TN2017000355A1 (es)
TW (1) TWI627177B (es)
WO (1) WO2016137788A1 (es)
ZA (1) ZA201704293B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
CA2977667C (en) 2015-03-19 2019-08-20 Eli Lilly And Company Aminothiazine compounds useful as selective bace1 inhibitors
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20180496A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN109069482B (zh) 2016-04-01 2022-04-05 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物
CN109641052A (zh) * 2016-08-18 2019-04-16 伊莱利利公司 BACE-1抑制剂和抗-N3pGlu Aβ抗体的组合疗法
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PE20200342A1 (es) 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
MX393586B (es) 2017-05-22 2025-03-24 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG162790A1 (en) 2005-06-14 2010-07-29 Schering Corp Aspartyl protease inhibitors
BRPI0906962B8 (pt) * 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
WO2010038686A1 (ja) 2008-09-30 2010-04-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規な縮合アミノジヒドロチアジン誘導体
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
WO2011071057A1 (ja) 2009-12-09 2011-06-16 塩野義製薬株式会社 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物
US20120245155A1 (en) 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012162334A1 (en) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
GB201212816D0 (en) * 2012-07-19 2012-09-05 Eisai Ltd Novel compounds
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
JO3318B1 (ar) * 2013-06-18 2019-03-13 Lilly Co Eli مثبطات bace
AR104241A1 (es) * 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos

Also Published As

Publication number Publication date
US20160244465A1 (en) 2016-08-25
KR101945139B1 (ko) 2019-02-01
TN2017000355A1 (en) 2019-01-16
AU2016223072A1 (en) 2017-07-13
BR112017013936A2 (pt) 2018-01-02
SG11201705764SA (en) 2017-08-30
GT201700185A (es) 2018-11-23
PH12017501523A1 (en) 2018-02-05
CN107257801A (zh) 2017-10-17
CA2972098A1 (en) 2016-09-01
JP6111001B1 (ja) 2017-04-05
SI3262051T1 (sl) 2019-11-29
EP3262051B1 (en) 2019-10-02
WO2016137788A1 (en) 2016-09-01
AU2016223072B2 (en) 2018-11-15
AR103680A1 (es) 2017-05-24
CL2017002090A1 (es) 2018-04-13
TW201643170A (zh) 2016-12-16
MX2017010861A (es) 2017-12-11
PE20171337A1 (es) 2017-09-13
JP2017511806A (ja) 2017-04-27
US9522923B2 (en) 2016-12-20
DOP2017000178A (es) 2017-09-15
EA031546B1 (ru) 2019-01-31
ZA201704293B (en) 2019-01-30
EP3262051A1 (en) 2018-01-03
KR20170103971A (ko) 2017-09-13
TWI627177B (zh) 2018-06-21
NZ732940A (en) 2019-06-28
IL252969A0 (en) 2017-08-31
CN107257801B (zh) 2019-08-13
EA201791684A1 (ru) 2017-12-29
CO2017008382A2 (es) 2017-11-30
MX367940B (es) 2019-09-12
CR20170315A (es) 2017-08-14

Similar Documents

Publication Publication Date Title
ECSP17054980A (es) Inhibidores selectivos de bace1
DK3873903T3 (da) Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
MX2019004626A (es) Compuesto de piridona como inhibidor de c-met.
AR095039A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
AR101995A1 (es) COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6
EA201691421A1 (ru) Гетероарилы и их применение
DK3774817T3 (da) Bcl6-hæmmere
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
DK3544981T3 (da) Benzodiazoliumforbindelser som enac-inhibitorer
DK3890828T3 (da) Heteroaromatiske forbindelser som vanin-hæmmere
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CR20170050A (es) Compuestos de azetidiniloxifenilpirrolidina
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
DK3790873T3 (da) 1h-indazol-3-carboxamidforbindelser som glycogensynthase-kinase-3-beta-inhibitorer
AR104241A1 (es) Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt